ATE536349T1 - In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren - Google Patents
In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitorenInfo
- Publication number
- ATE536349T1 ATE536349T1 AT06836157T AT06836157T ATE536349T1 AT E536349 T1 ATE536349 T1 AT E536349T1 AT 06836157 T AT06836157 T AT 06836157T AT 06836157 T AT06836157 T AT 06836157T AT E536349 T1 ATE536349 T1 AT E536349T1
- Authority
- AT
- Austria
- Prior art keywords
- benzimidazole
- phenyl
- carbonic acid
- acid amides
- parp inhibitors
- Prior art date
Links
- 239000012661 PARP inhibitor Substances 0.000 title 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 title 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 abstract 3
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 abstract 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 3
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72168305P | 2005-09-29 | 2005-09-29 | |
| PCT/US2006/038169 WO2007041357A1 (en) | 2005-09-29 | 2006-09-28 | 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE536349T1 true ATE536349T1 (de) | 2011-12-15 |
Family
ID=37692513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06836157T ATE536349T1 (de) | 2005-09-29 | 2006-09-28 | In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8697736B2 (de) |
| EP (1) | EP1957477B1 (de) |
| JP (1) | JP5227796B2 (de) |
| CN (1) | CN101316834A (de) |
| AT (1) | ATE536349T1 (de) |
| CA (1) | CA2623822C (de) |
| ES (1) | ES2378692T3 (de) |
| WO (1) | WO2007041357A1 (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59911249D1 (de) | 1998-11-03 | 2005-01-13 | Abbott Gmbh & Co Kg | Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung |
| US7728026B2 (en) * | 2005-04-11 | 2010-06-01 | Abbott Laboratories, Inc. | 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors |
| WO2007059230A2 (en) * | 2005-11-15 | 2007-05-24 | Abbott Laboratories | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
| EP2007733B1 (de) * | 2006-04-03 | 2016-05-25 | MSD Italia S.r.l. | Amidsubstituierte indazol- und benzotriazolderivate als inhibitoren der poly(adp-ribose)polymerase (parp) |
| CA2647373C (en) * | 2006-05-02 | 2014-03-18 | Abbott Laboratories | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
| AR064777A1 (es) * | 2007-01-10 | 2009-04-22 | Inst Di Reserche D Biolog Mole | Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp) |
| US8067613B2 (en) * | 2007-07-16 | 2011-11-29 | Abbott Laboratories | Benzimidazole poly(ADP ribose)polymerase inhibitors |
| CN103169973A (zh) * | 2007-11-12 | 2013-06-26 | 彼帕科学公司 | 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌 |
| JP5989965B2 (ja) | 2008-01-08 | 2016-09-07 | メルク シャープ エンド ドーム リミテッド | ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩 |
| WO2009099736A2 (en) | 2008-02-06 | 2009-08-13 | Lead Therapeutics, Inc. | Benzoxazole carboxamide inhibitors of poly(adp-ribose)polymerase (parp) |
| WO2010083199A1 (en) * | 2009-01-19 | 2010-07-22 | Abbott Laboratories | Benzthiazole inhibitors of poly(adp-ribose)polymerase |
| WO2010115736A2 (en) * | 2009-04-02 | 2010-10-14 | Merck Serono S.A. | Dihydroorotate dehydrogenase inhibitors |
| ES2604305T3 (es) * | 2009-07-14 | 2017-03-06 | Nerviano Medical Sciences S.R.L. | 3-oxo-2,3-dihidro-1H-isoindol-4-carboxamida con inhibición selectiva de PARP-1 |
| ES2759751T3 (es) * | 2009-07-14 | 2020-05-12 | Nerviano Medical Sciences Srl | 3-oxo-2,3-dihidro-1H-isoindol-4-carboxamidas |
| JP2013526514A (ja) | 2010-05-10 | 2013-06-24 | ラディカル・セラピューティックス・インコーポレイテッド | リポ酸およびニトロキシド誘導体およびその使用 |
| WO2013014038A1 (en) * | 2011-07-26 | 2013-01-31 | Nerviano Medical Sciences S.R.L. | 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivatives as parp-1 inhibitors |
| ES2664050T3 (es) | 2012-10-15 | 2018-04-18 | Albemarle Corporation | Procesos para la síntesis de la 2-amino-4,6-dimetoxibenzamida y otros compuestos de benzamida |
| CN102964354B (zh) * | 2012-11-16 | 2014-08-13 | 江苏先声药业有限公司 | 一类噻吩并咪唑衍生物及其应用 |
| JP6457696B2 (ja) | 2015-07-23 | 2019-01-23 | アンスティテュ・キュリＩｎｓｔｉｔｕｔ Ｃｕｒｉｅ | 癌を処置するためのＤｂａｉｔ分子とＰＡＲＰインヒビターとの組合せの使用 |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| JP6590226B2 (ja) * | 2016-05-11 | 2019-10-16 | 株式会社シード探索研究所 | オキサアジリジン化合物およびその製造方法 |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| KR20200121800A (ko) | 2018-01-05 | 2020-10-26 | 싸이브렉사 1, 인크. | 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법 |
| KR20200130856A (ko) | 2018-03-13 | 2020-11-20 | 옹쎄오 | 암 치료에서 획득한 내성에 대한 디베이트 분자 |
| US20210347758A1 (en) | 2018-10-03 | 2021-11-11 | Tesaro, Inc. | Crystalline Forms of Niraparib Freebase |
| CA3142890A1 (en) * | 2019-06-14 | 2020-12-17 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| TW202116356A (zh) | 2019-07-10 | 2021-05-01 | 美商斯布雷克薩三號公司 | 作為治療劑之微管靶向藥劑之肽結合物 |
| CN114341162B (zh) | 2019-07-10 | 2025-10-17 | 赛博克萨2公司 | 作为治疗剂的细胞毒素的肽缀合物 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| US20240093250A1 (en) | 2021-01-08 | 2024-03-21 | Cybrexa 2, Inc. | Process for preparing a conjugate linking moiety |
| WO2022155172A1 (en) | 2021-01-13 | 2022-07-21 | Cybrexa 3, Inc. | Peptide conjugates of therapeutics |
| KR20260030809A (ko) | 2023-06-21 | 2026-03-06 | 테트라곤 바이오사이언시스 엘티디 | Hr 능숙형 암을 치료하는 방법에 사용하기 위한 데옥시시티딘 유도체 및 parp 억제제를 포함하는 조합 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4093726A (en) * | 1976-12-02 | 1978-06-06 | Abbott Laboratories | N-(2-benzimidazolyl)-piperazines |
| US6911462B2 (en) * | 1998-05-22 | 2005-06-28 | Avanir Pharmaceuticals | Benzimidazole compounds for regulating IgE |
| GB9815880D0 (en) * | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
| DE59911249D1 (de) * | 1998-11-03 | 2005-01-13 | Abbott Gmbh & Co Kg | Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung |
| DK1131301T3 (da) | 1998-11-17 | 2006-01-09 | Abbott Gmbh & Co Kg | 2-phenylbenzimidazoler og 2-phenylindoler, fremstilling af anvendelse heraf |
| CA2352554C (en) | 1998-11-27 | 2006-10-10 | Basf Aktiengesellschaft | Substituted benzimidazoles and their use as parp inhibitors |
| DE19918211A1 (de) | 1999-04-22 | 2000-10-26 | Basf Ag | Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung |
| DE19920936A1 (de) * | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
| DE10021468A1 (de) * | 2000-05-04 | 2001-11-08 | Basf Ag | Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen |
| US7122679B2 (en) * | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
| HU0301154D0 (en) * | 2003-04-28 | 2003-07-28 | Hideg Kalman Dr | Pharmaceutical composition |
| TWI375673B (en) * | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| US7728026B2 (en) * | 2005-04-11 | 2010-06-01 | Abbott Laboratories, Inc. | 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors |
| WO2007059230A2 (en) * | 2005-11-15 | 2007-05-24 | Abbott Laboratories | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
| ME02121B (de) * | 2006-01-17 | 2014-06-30 | Abbvie Ireland Unlimited Co | Kombinationstherapie mit PARP Inhibitoren |
| CA2647373C (en) * | 2006-05-02 | 2014-03-18 | Abbott Laboratories | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
| US8067613B2 (en) * | 2007-07-16 | 2011-11-29 | Abbott Laboratories | Benzimidazole poly(ADP ribose)polymerase inhibitors |
-
2006
- 2006-09-28 EP EP06836157A patent/EP1957477B1/de active Active
- 2006-09-28 ES ES06836157T patent/ES2378692T3/es active Active
- 2006-09-28 CA CA2623822A patent/CA2623822C/en not_active Expired - Fee Related
- 2006-09-28 WO PCT/US2006/038169 patent/WO2007041357A1/en not_active Ceased
- 2006-09-28 CN CNA2006800443709A patent/CN101316834A/zh active Pending
- 2006-09-28 JP JP2008533692A patent/JP5227796B2/ja not_active Expired - Fee Related
- 2006-09-28 AT AT06836157T patent/ATE536349T1/de active
- 2006-09-29 US US11/536,994 patent/US8697736B2/en active Active
-
2014
- 2014-04-11 US US14/250,698 patent/US20140296235A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101316834A (zh) | 2008-12-03 |
| CA2623822C (en) | 2013-11-12 |
| JP5227796B2 (ja) | 2013-07-03 |
| US20140296235A1 (en) | 2014-10-02 |
| CA2623822A1 (en) | 2007-04-12 |
| EP1957477B1 (de) | 2011-12-07 |
| WO2007041357A1 (en) | 2007-04-12 |
| US20070179136A1 (en) | 2007-08-02 |
| US8697736B2 (en) | 2014-04-15 |
| ES2378692T3 (es) | 2012-04-17 |
| JP2009510106A (ja) | 2009-03-12 |
| EP1957477A1 (de) | 2008-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE536349T1 (de) | In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren | |
| ATE461923T1 (de) | Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren | |
| EA200600689A1 (ru) | Замещённые бензазолы и их применение в качестве ингибиторов raf киназы | |
| PT2420234E (pt) | 1h-benzimidazole-4-carboxamidas substituídas com um carbono quaternário na posição 2 como inibidores de parp para uso no tratamento do cancro | |
| MX2009000657A (es) | Composiciones y metodos para el tratamiento de mucositis. | |
| EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
| EA200970447A1 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| ATE543819T1 (de) | Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit | |
| UA93351C2 (uk) | Похідні фталазіну як інгібітори parp | |
| ATE368031T1 (de) | Neue gamma secretase inhibitoren | |
| EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
| ZA200706010B (en) | 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-hetero-ayryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity | |
| CY1110498T1 (el) | Παραγωγα πυραζολης ως αναστολεις των κινασων τυροσινης υποδοχεα | |
| NO20054970L (no) | Arylsubstituerte byrazolforbindelser anvendbare som kinaseinhibitorer | |
| NO20073783L (no) | Pyrrolidininhibitorer for IAP | |
| NO20091620L (no) | Boronsyre og estere som inhibitorer av fettsyreamidhydrolaser | |
| ATE549336T1 (de) | Heteroarylverbindungen,zusammensetzungen daraus und ihre verwendung als proteinkinasehemmer | |
| TW200744586A (en) | Therapeutic compounds | |
| EA200701396A1 (ru) | Триазолофталазины в качестве ингибиторов pde-2 | |
| MX2010002449A (es) | Compuestos de piperidina tipo quinoxalina sustituida y uso de los mismsos. | |
| TW200740773A (en) | Diaminopyrimidines as P2X3 and P2X2/3 modulators | |
| EA200701840A1 (ru) | N-сульфонилпирролы и их применение в качестве ингибиторов гистондезацетилазы | |
| TW200745028A (en) | Novel sulphonylpyrroles | |
| ATE553093T1 (de) | Indazolderivate zur hemmung von trpv1 und verwendungen davon | |
| TW200745027A (en) | Novel sulphonylpyrroles |